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METHODOLOGY Open Access
Sample size estimation for randomised
controlled trials with repeated assessment
of patient-reported outcomes: what
correlation between baseline and follow-up
outcomes should we assume?
Stephen J. Walters* , Richard M. Jacques, Inês Bonacho dos Anjos Henriques-Cadby, Jane Candlish,
Nikki Totton and Mica Teo Shu Xian
Abstract
Background: Patient-reported outcome measures (PROMs) are now frequently used in randomised controlled trials
(RCTs) as primary endpoints. RCTs are longitudinal, and many have a baseline (PRE) assessment of the outcome and
one or more post-randomisation assessments of outcome (POST). With such pre-test post-test RCT designs there
are several ways of estimating the sample size and analysing the outcome data: analysis of post-randomisation
treatment means (POST); analysis of mean changes from pre- to post-randomisation (CHANGE); analysis of
covariance (ANCOVA).
Sample size estimation using the CHANGE and ANCOVA methods requires specification of the correlation between
the baseline and follow-up measurements. Other parameters in the sample size estimation method being
unchanged, an assumed correlation of 0.70 (between baseline and follow-up outcomes) means that we can halve
the required sample size at the study design stage if we used an ANCOVA method compared to a comparison of
POST treatment means method. So what correlation (between baseline and follow-up outcomes) should be
assumed and used in the sample size calculation? The aim of this paper is to estimate the correlations between
baseline and follow-up PROMs in RCTs.
Methods: The Pearson correlation coefficients between the baseline and repeated PROM assessments from 20 RCTs
(with 7173 participants at baseline) were calculated and summarised.
Results: The 20 reviewed RCTs had sample sizes, at baseline, ranging from 49 to 2659 participants. The time points
for the post-randomisation follow-up assessments ranged from 7 days to 24 months; 464 correlations, between
baseline and follow-up, were estimated; the mean correlation was 0.50 (median 0.51; standard deviation 0.15; range
− 0.13 to 0.91).
Conclusions: There is a general consistency in the correlations between the repeated PROMs, with the majority
being in the range of 0.4 to –0.6. The implications are that we can reduce the sample size in an RCT by 25% if we
use an ANCOVA model, with a correlation of 0.50, for the design and analysis. There is a decline in correlation
amongst more distant pairs of time points.
Keywords: Sample size estimation, Review, Randomised controlled trials, Health Technology Assessment, Publicly
funded, Correlations, ANCOVA, Patient-reported outcome measures
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Background
Patient-reported outcome measures (PROMs) are now
frequently used in randomised controlled trials (RCTs)
as primary endpoints. All RCTs are longitudinal, and
many have a baseline, or pre-randomisation (PRE) as-
sessment of the outcome, and one or more post-
randomisation assessments of outcome (POST).
For such pre-test post-test RCT designs, using a con-
tinuous primary outcome, the sample size estimation
and the analysis of the outcome can be done using one
of the following methods:
1. Analysis of post-randomisation treatment means
(POST)
2. Analysis of mean changes from pre- to post-
randomisation (CHANGE)
3. Analysis of covariance (ANCOVA).
For brevity (and following Frison and Pocock’s nomen-
clature [1]), these methods will be referred to as POST,
CHANGE and ANCOVA respectively.
Sample size calculations are now mandatory for many
research protocols and are required to justify the size of
clinical trials in papers before they will be accepted for
publication by journals [2]. Thus, when an investigator is
designing a study to compare the outcomes of an inter-
vention, an essential step is the calculation of sample
sizes that will allow a reasonable chance (power) of de-
tecting a pre-determined difference (effect size) in the
outcome variable, when the intervention is actually ef-
fective, at a given level of significance. Sample size is
critically dependent on the type of summary measure,
the proposed effect size and the method of calculating
the test statistic [3]. For example, for a given power and
significance level, the sample size is inversely propor-
tional to the square of the effect size, so halving the ef-
fect size will quadruple the sample size. For simplicity,
this paper will assume that we are interested in compar-
ing the effectiveness (or superiority) of a new treatment
compared to a standard treatment, at a single point in
time post-randomisation.
Sample size
In a two-group study with a Normally distributed out-
come, comparing POST-randomisation mean outcomes
between two groups, the number of subjects per group
nPOST assuming equal sample sizes and equal standard
deviations (SDs) per group for a two-sided significance
level α and power 1 – β is [4]:
nPOST per group ¼
2σ2 Z1−α=2 þ Z1−β
 2
δ2
;
where:
δ is the target or anticipated difference in mean out-
comes between the two groups
σ is the SD of the outcome post-randomisation (which
is assumed to be the same in both groups)
Z1 – α/2 and Z1 – β are the appropriate values from the
standard normal distribution for the 100 (1 – α/2) and
100 (1 – β) percentiles respectively.
Consider a two-group study with a Normally distrib-
uted outcome, with a single baseline and single post-
randomisation assessment of outcomes. Comparing
mean outcomes between two groups, adjusted for the
baseline or pre-randomisation value of the outcome,
using an ANCOVA model for the number of subjects
per group nANCOVA (assuming equal sample sizes and
equal SDs, at baseline and post-randomisation, per
group) for a two-sided significance level α and power 1
– β is:
nANCOVA per group ¼
2σ2 Z1−α=2 þ Z1−β
 2
δ2
1−ρ2
 
:
Here, ρ denotes the correlation between the baseline
and post-randomisation outcomes and σ is the post-
randomisation SD, which is assumed to be the same as
the baseline SD [1, 5]. Machin et al. [5] refer to the (1 –
ρ2) term as the ’design effect’ (DE).
In a two-group study with a Normally distributed out-
come, comparing the mean change in outcomes (i.e.
post-randomisation outcome – baseline) between two
groups, the number of subjects per group nCHANGE (as-
suming equal sample sizes and equal SDs, at baseline
and post-randomisation, per group) for a two-sided sig-
nificance level α and power 1 – β is:
nCHANGE per group ¼
2σ2 Z1−α=2 þ Z1−β
 2
δ2c
2−2ρf g:
Here, δc is the target or anticipated difference in mean
change in outcomes between the two groups and σ is
the post-randomisation SD that is assumed to be the
same as the baseline SD. If the expected mean values of
the baseline outcomes are the same in both groups,
which is likely in an RCT, then δc is the same as δ.
Figure 1 shows the relationship between the total sam-
ple size and the correlation between the baseline and
post-randomisation outcomes, for the three methods of
sample size estimation (POST, CHANGE and
ANCOVA) with a 5% two-sided significance level, 90%
power, a target difference (a difference in post-treatment
means or a difference in mean changes) of 0.50 and an
SD of 1.0. Figure 1 shows how the total sample size is
constant for POST irrespective of the baseline and post-
randomisation follow-up correlation; the sample size de-
clines as the correlation increases for ANCOVA and
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CHANGE; and that for correlations above 0.5 the sam-
ple size for ANCOVA is always the lowest and is less
than or equal to the sample size for CHANGE.
Example
The SELF study [6] was a multicentre, pragmatic, un-
blinded, parallel-group randomised control superiority
trial designed to evaluate the clinical effectiveness of a
self-managed single exercise programme versus usual
physiotherapy treatment for rotator cuff tendinopathy
(pain or weakness in the shoulder muscles). The inter-
vention was a programme of self-managed exercise pre-
scribed by a physiotherapist in relation to the most
symptomatic shoulder movement. The control group re-
ceived usual physiotherapy treatment. The primary out-
come measure was the total score on the Shoulder Pain
and Disability Index (SPADI) at 3 months post-
randomisation. The SPADI Shoulder Score ranges from
0, being the best outcome (less disability), to 100 the
worst (greater disability).
The original sample size calculation for the SELF trial
assumed that a 10-point difference in the mean 3
months post-randomisation SPADI scores between the
intervention and control groups would be regarded as a
minimum clinical important difference (MCID). It as-
sumed an SD of 24 points, a power of 80% and a (two-
sided) significance level of 5%, meaning that using the
POST sample size formula, 91 participants per group
were required (182 in total). However, in light of new in-
formation from an external pilot study, the investigators
undertook a sample size re-estimation (SSR) calculation,
which was approved by the ethics committee. The new
information related to a narrower estimate of population
variance from an external pilot RCT (n = 24) of 16.8
points on the SPADI and, additionally, a correlation be-
tween baseline and 3 months SPADI scores of 0.5. Using
the ANCOVA sample size formula, with an SD of 17
points; correlation between baseline and 3 months
SPADI scores of 0.50, 80% power, 5% two-sided signifi-
cance and a MCID (as before) of 10 points, it was esti-
mated that 34 participants per group were required (68
in total). This contrasts with a sample size of 45 per
group using the POST means formula with the revised
SD of 17 points. Thus, with a correlation of 0.50 be-
tween baseline and follow-up, using the ANCOVA
method for sample size estimation, we can reduce the
sample size by approximately 25% (i.e. 1–0.52) compared
to the POST treatment means method.
Should the method of sample size estimation mirror
the proposed method of statistical analysis (of the out-
come data)? That is, if an ANCOVA model is likely to
be used in the statistical analysis of the collected out-
come data, should an ANCOVA method that allows for
the correlation also be used in the sample size estima-
tion method? And if so, what correlation (between base-
line and follow-up outcomes) should be assumed and
Fig. 1 Relationship between the total sample size and the correlation between the baseline and post-randomisation outcomes for the three
methods of sample size estimation (POST, CHANGE and ANCOVA)
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used in the sample size estimation? Other factors/pa-
rameters in the sample size estimation method being un-
changed, an assumed correlation of 0.70 (between
baseline and follow-up outcomes) means that we can
halve the require sample size at the study design stage, if
we used an ANCOVA method compared to a compari-
son of POST treatment means method. It is, however,
paramount to assess how realistic a correlation of 0.50
or 0.70 between baseline and post-randomisation out-
comes is, and to make evidence-based assumptions on
these values, as an overestimated correlation could result
in an underpowered study. The aim of this paper is to
estimate the observed correlations between baseline and
post-randomisation follow-up PROMs from a number of
RCTs, bridging a gap in the evidence.
Methods
Data sources
This was a secondary analysis of RCTs with continuous
patient-reported outcomes (both primary and secondary)
undertaken in the School of Health and Related Re-
search (ScHARR) at the University of Sheffield published
between 1998 and 2019. Secondary ethics approval was
gained through the University of Sheffield ScHARR Eth-
ics Committee (Reference 024041).
Statistical analysis
For each included trial, the correlation between baseline
and post-randomisation outcomes was calculated using
the Pearson correlation coefficient [7]. Given a set of n
pairs of observations (x1, y1), (x2, y2), …, (xn, yn), with
means x and y respectively, then the Pearson correlation
coefficient r is given by:
r ¼
Xn
i¼1
yi−yð Þ xi−xð ÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXn
i¼1
yi−yð Þ
2
Xn
i¼1
xi−xð Þ
2
s
with a standard error SE(r) = SEðrÞ ¼
ﬃﬃﬃﬃﬃﬃﬃ
1−r2
n−2
q
.
A variety of summary statistics for the baseline and
post-randomisation correlations were calculated, includ-
ing (1) the unweighted sample mean and median; (2) a
weighted sample mean, using the fixed effect inverse
variance method [4], and (3) a sample mean with allow-
ance for clustering by trial derived from a multilevel
mixed-effects linear model with a random effect for the
trial using restricted maximum likelihood estimation
(REML) [8]. The correlations were calculated overall and
then split by trial, outcome and time point.
Results
Trials
Table 1 shows a summary of the 20 RCTs included in
the analysis. Various outcome measures were used in
the trials for both the primary and secondary outcomes.
Table 2 provides a brief description of the outcome mea-
sures and how they were scaled. Three of the outcome
measures, the Clinical Outcomes in Routine Evaluation -
Outcome Measure (CORE-OM), Pelvic Organ Prolapse/
Urinary Incontinence Sexual Questionnaire (PISQ-31)
and SPADI, have a total score and various subscales:
both were included in the analysis. The 20 included
RCTs had sample sizes (at baseline) ranging from 49 to
2659 participants. The time points for the post-
randomisation to follow-up assessments ranged from 7
days to 24months. The maximum sample size for the
baseline follow-up correlations ranged from 39 to 2659
participants. Four-hundred and sixty-four correlations
between baseline and follow-up were estimated in the 20
trials. Table 1 shows, for example, that the Leg Ulcer
trial (Trial 1) had 9 outcomes all assessed at 2 post-
randomisation time points (3 and 12months), giving a
total of 2 × 9 = 18 correlations. The median number of
outcomes per trial was 9 and ranged from 1 (in the 3Mg
trial) to 15 (AIM-High, PLINY and IPSU). The median
number of correlations calculated per trial was 16.5 and
ranged from 1 (in the 3Mg trial) to 65 (in the DiPALS
trial). The median number of post-randomisation
follow-up time points across the 20 trials was 2.5 and
ranged from 1 to 6.
Correlation
Figure 2 shows a histogram of the 464 estimated base-
line to follow-up correlations. The histogram is reason-
ably symmetrical, and the overall mean correlation was
0.50 (median of 0.51). The baseline to follow-up correla-
tions ranged from − 0.13 to 0.91 with an interquartile
range of 0.41 to 0.60. Since the sample sizes for the trials
varied from 49 to 2659 participants, a weighted estimate
of the mean correlation, using the inverse variance
method, was 0.51. Since the 464 correlation estimates
were from 20 trials and the correlations were nested or
clustered with trials, the estimated mean correlation
after allowing for clustering by trial, using a multilevel
mixed-effects linear regression model (with a random ef-
fect or intercept for the trial), was 0.49 (95% confidence
interval [CI] 0.45 to 0.53). These other summary esti-
mates were very similar to the simple unweighted mean
value of 0.50.
Table 3 shows the baseline to post-randomisation
follow-up correlations aggregated by trial. The largest
average correlations per trial showed a mean of 0.67 ob-
served in the PLINY trial; the lowest average correlations
were observed in the POLAR trial. The trial with the
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Table 1 Summary of the 20 randomised controlled trials
Trial name Trial population Age
range
(years)
Outcome
measures
No. of
outcomes
Time points
post-
randomisation
No. of
time
points
No. of
correlations
Sample
size at
baseline
Max
N
a
Reference Year of
publication
1 Leg Ulcer Leg ulcers 32 to
97
EQ-5D, SF-36 9 3, 12 months 2 18 233 200 [9] 1998
2 NAMEIT Early severe
rheumatoid
arthritis
18 to
75
SF-36, SF-6D 9 2, 4, 6, 8, 10,
12 months
6 54 222 222 [10] 2000
3 Homeopathy
for CFS
Chronic fatigue
syndrome (CFS)
20 to
62
MFI 5 6 months 1 5 103 85 [11] 2004
4 Acupuncture Low back pain 20 to
64
SF-36 8 3, 12, 24
months
3 24 239 217 [12] 2005
5 Knee
Replacement
Osteoarthritis
patients
undergoing
total knee
replacement
51 to
92
SF-36,
WOMAC
14 3 months 1 14 151 114 [13] 2005
6 FED Older (aged ≥
65) hospitalised
patients with
acute illness
65 to
93
Barthel, SF-36 9 1.5, 6 months 2 18 445 225 [14] 2006
7 AIM-High Malignant
melanoma
18 to
77
EORTC QLQ-
C30
15 6, 12, 18, 24
months
4 60 444 392 [15] 2006
8 PoNDER New mothers 18 to
45
CORE-OM,
EPDS,b SF-36,
SF-6D
9 4.5, 10.5, 16.5
months
3 26 2659 2659 [16] 2009
9 COPD Chronic
obstructive
pulmonary
disease (COPD)
49 to
86
EQ-5D, SF-36,
SF-6D
12 2, 6, 12, 18
months
4 48 238 172 [17] 2010
10 Corn Plasters Foot corns 18 to
90
EQ-5D, EQ-
5D VAS, VAS
Pain
3 3, 6, 9, 12
months
4 12 201 182 [18] 2013
11 PLINY Independently
living older
people (aged
≥ 75)
75 to
95
EQ-5D, EQ-
5D VAS,
GSES, ONS
Well-being,
PHQ-9, SF-36
15 6 months 1 15 157 56 [19] 2014
12 3Mg Adults with
acute severe
asthma in the
emergency
department
16 to
88
EQ-5D 1 1 month 1 1 932 437 [20] 2014
13 SELF Shoulder
rotator cuff
tendinopathy
23 to
83
SPADI 3 3, 6, 12
months
3 9 85 59 [6] 2016
14 BEADS Post-stroke
depression
31 to
97
EQ-5D, EQ-
5D VAS, PHQ-
9
3 6 months 1 3 49 39 [21] 2016
15 DiPALS Amyotrophic
lateral sclerosis
(ALS)
23 to
83
EQ-5D,
SAQLI, SF-36
13 2, 3, 6, 9, 12
months
5 65 74 55 [22] 2016
16 Lifestyle
Matters
Independently
living older
people (aged
≥ 65)
65 to
92
EQ-5D, EQ-
5D VAS,
GSES, PHQ-9,
SF-36
14 6, 24 months 2 28 288 262 [23] 2017
17 IPSU Women with
urinary
incontinence
and sexual
21 to
70
EQ-5D, PISQ-
31, SF-36
15 6 months 1 15 107 66 [24] 2018
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widest range of correlations was the PRACTICE trial.
Figure 3 shows a box and whisker plot of how the ob-
served baseline to follow-up correlations varied across
the 20 RCTs along with the overall median correlation.
There was considerable intertrial variation in the corre-
lations, and it should be noted that some of the trials
had less than or equal to six baseline to follow-up corre-
lations estimated (3Mg [N = 1 outcome and correlation],
BEADS [N = 3], Homeopathy [N = 5] and PRACTICE
[N = 6]).
The time points for the post-randomisation follow-up
assessments ranged from 7 days to 24 months. Table 4
shows the baseline to post-randomisation follow-up cor-
relations by post-randomisation follow-up time point.
Figure 4 shows a scatter plot of the baseline to follow-up
correlations by post-randomisation follow-up time point
for the 464 correlations from the 20 trials. Although it is
not obvious from the scatter plot, a multilevel mixed-
effects linear regression model (with a random intercept
for the trial) suggests a small decline in the baseline to
post-randomisation follow-up correlations the further
the time points are apart. The estimated regression coef-
ficient from the model was − 0.003 (95% CI − 0.006 to −
0.001; P = 0.005). This implies that for every unit or 1-
month increase in the time from baseline to the post-
randomisation follow-up the correlation declines by
0.003 point. Figures 5 and 6 show how the correlations
change over time for the Short Form Health Survey (SF-
36) outcomes (282 correlations and 12 trials) and the
EuroQol five dimension scale (EQ-5D) Utility score
outcome (29 correlations and 12 trials). A similar pat-
tern to the overall pattern is observed for these specific
outcomes with a small decline (0.003 for the SF-36 and
0.002 for the EQ-5D) in baseline to follow-up correla-
tions over time.
Table 5 shows the baseline to post-randomisation cor-
relations by outcome. The SF-36 was the most popular
outcome and used in 12 out of the 20 trials. The correla-
tions for SF-36 outcomes and its various dimensions (12
trials and n = 282 correlations) showed a mean of 0.51
(median 0.53), range 0.06 to 0.91. The second most
popular outcome was the EQ-5D, which was used in 12
of the trials as well. Correlations for EQ-5D outcomes
only (12 trials and n = 50 correlations) showed a mean of
0.49 (median 0.51), range − 0.13 to 0 87. Three of the
outcome measures, the CORE-OM, PISQ-31 and
SPADI, in Table 5 have a total score and various sub-
scales. There was no clear pattern in the correlations
and no reliable evidence that the total scale score corre-
lated more highly than an individual subscale score.
Discussion
The 20 reviewed RCTs had sample sizes, at baseline,
ranging from 49 to 2659 participants. The time points
for the post-randomisation follow-up assessments
ranged from 7 days to 24months; 464 correlations be-
tween baseline and follow-up were estimated; the mean
correlation was 0.50 (median 0.51; SD 0.15; range − 0.13
to 0.91).
Table 1 Summary of the 20 randomised controlled trials (Continued)
Trial name Trial population Age
range
(years)
Outcome
measures
No. of
outcomes
Time points
post-
randomisation
No. of
time
points
No. of
correlations
Sample
size at
baseline
Max
N
a
Reference Year of
publication
dysfunction
18 POLAR Lumbar
radicular
syndrome (LRS)
23 to
71
Back Pain
VAS, EQ-5D,
EQ-5D VAS,
Leg Pain VAS,
ODI
5 1.5, 3, 6
months
3 15 80 73 [25] 2018
19 PRACTICE COPD 40 to
92
EQ-5D, EQ-
5D VAS
2 0.25, 1, 3
months
3 6 55 42 [26] 2018
20 STEPWISE Schizophrenia 18 to
71
B-IPQ, BPRS,
EQ-5D, EQ-
5D VAS, PHQ-
9, RAND SF-
36
14 3, 12 months 2 28 412 358 [27] 2018
464 7173 5915
aMax N is the maximum sample size for the baseline and post-randomisation follow-up correlations
bFor the PoNDER trial the EPDS was measured at baseline and at 4.5 and 10.5 months post-randomisation
Abbreviations: Barthel Barthel Index for Activities of Daily Living (ADL), B-IPQ Brief Illness Perception Questionnaire, BPRS Brief Psychiatric Rating Scale, CORE-OM
Clinical Outcomes in Routine Evaluation-Outcome Measure, EORTC QLQ European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire, EPDS Edinburgh Postnatal Depression Scale, EQ-5D EuroQol Five Dimension, GSES General Self-Efficacy Scale, MFI Multidimensional Fatigue
Inventory, ODI Oswestry Disability Index, ONS Office for National Statistics Well-being Questionnaire, PHQ-9 Patient Health Questionnaire, PISQ-31 Pelvic Organ
Prolapse/Urinary Incontinence Sexual Questionnaire, RAND SF-36 Research and Development 36-item Short Form Survey Instrument, SAQLI Sleep Apnea Quality of
Life Index, SF-36 Short Form (36 item) Health Survey, SF-6D Short Form Six Dimension, SPADI Shoulder Pain and Disability Index, VAS visual analogue scale,
WOMAC Western Ontario and McMaster Universities Osteoarthritis Index
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Table 2 Description of the outcome measures used in 20 randomised controlled trials and how they are scaled/scored
Outcome name Trials Score range Correlations Reference
1 B-IPQ 1 0 to 10 2 [28]
2 Back Pain VAS 1 0 to 10 3 [29]
3 Barthel score 1 0 to 20 2 [30]
4 BPRS 1 0 to 126 2 [31]
5 CORE Life functioning dimension 1 0 to 4 3 [32]
6 CORE Risk/harm dimension 1 0 to 4 3
7 CORE Problems/symptoms dimension 1 0 to 4 3
8 CORE Subjective well-being dimension 1 0 to 4 3
9 CORE total score 1 0 to 4 3
10 EORTC Appetite Loss 1 0 to 100 4 [33]
11 EORTC Cognitive Functioning 1 0 to 100 4
12 EORTC Constipation 1 0 to 100 4
13 EORTC Diarrhoea 1 0 to 100 4
14 EORTC Dyspnoea 1 0 to 100 4
15 EORTC Emotional Functioning 1 0 to 100 4
16 EORTC Fatigue 1 0 to 100 4
17 EORTC Financial Difficulties 1 0 to 100 4
18 EORTC Insomnia 1 0 to 100 4
19 EORTC Nausea 1 0 to 100 4
20 EORTC Pain 1 0 to 100 4
21 EORTC Physical Functioning 1 0 to 100 4
22 EORTC QoL 1 0 to 100 4
23 EORTC Role Functioning 1 0 to 100 4
24 EORTC Social Functioning 1 0 to 100 4
25 EPDS 1 0 to 30 2 [34]
26 EQ-5D Utility score 12 −0.56 to 1.00 29 [35]
27 EQ-5D VAS 8 0 to 100 21 [36]
28 GSES 2 10 to 40 3 [37]
29 Leg Pain VAS 1 0 to 10 3 [29]
30 MFI General Fatigue 1 4 to 20 1 [38]
31 MFI Mental Fatigue 1 4 to 20 1
32 MFI Physical Fatigue 1 4 to 20 1
33 MFI Reduced Activity 1 4 to 20 1
34 MFI Reduced Motivation 1 4 to 20 1
35 ODI 1 0 to 100 3 [39]
36 ONS Well-Being 1 0 to 40 1 [40]
37 PHQ-9 4 0 to 27 6 [41]
38 PISQ-31 Behaviour/Emotion 1 0 to 61 1 [42]
39 PISQ-31 Partner-Related Factor 1 0 to 24 1
40 PISQ-31 Physical Factor 1 0 to 40 1
41 PISQ-31 total score 1 0 to 125 1
42 SF-36 General Health 11 0 to 100 29 [43]
43 SF-36 Mental Health 11 1 to 100 29
44 SF-36 Pain 11 1 to 100 29
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Table 2 Description of the outcome measures used in 20 randomised controlled trials and how they are scaled/scored (Continued)
Outcome name Trials Score range Correlations Reference
45 SF-36 Physical Functioning 11 1 to 100 29
46 SF-36 Role-Emotional 11 1 to 100 29
47 SF-36 Role-Physical 11 1 to 100 29
48 SF-36 Social Functioning 11 1 to 100 29
49 SF-36 Vitality 11 1 to 100 29
50 SF-36 Health Change 1 1 to 100 2
51 SF-36 Mental Component Summary 7 NBS 17 [44]
52 SF-36 Physical Component Summary 7 NBS 17
53 SF-6D 4 0.29 to 1.00 14 [45]
54 Sleep Apnoea QoL 1 1 to 7 5 [46]
55 SPADI Disability 1 0 to 100 3 [47]
56 SPADI Pain 1 0 to 100 3
57 SPADI total score 1 0 to 100 3
58 VAS Pain 1 0 to 10 4 [48]
59 WOMAC Pain 1 0 to 20 1 [49]
60 WOMAC Physical Function 1 0 to 68 1
61 WOMAC Stiffness 1 0 to 8 1
NBS norm-based scoring: scores are standardised to have a mean of 50 and SD of 10
Fig. 2 Histogram of n = 464 correlations with overall median, 25th and 75th percentiles
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The 20 RCTs included in this study were a conveni-
ence sample of trials and data and may not be represen-
tative of the population of all trials with PROMs.
However, they include a wide range of populations and
disease areas, a variety of different interventions and
outcomes that are not untypical of other published trials.
We also reviewed detailed reports of 181 RCTs pub-
lished in the National Institute for Health Research
(NIHR) Health Technology Assessment (HTA) journal
from 2004 to the end of July 2017 and found 11 NIHR
HTA reports (and 12 outcomes) that had a sample size
calculation based on the ANCOVA model [50]. For
these 12 outcomes the mean baseline to follow-up cor-
relation that was assumed and used in the subsequent
sample size calculation was 0.49 (SD 0.09) and ranged
from 0.31 to 0.60. Thus, our results, with a mean correl-
ation of 0.50, are consistent with correlations used and
published in the NIHR HTA journal.
We observed a small decline in baseline to follow-
up correlations over time of − 0.003 per month. That
is, for every unit or 1-month increase in the time
from baseline to the post-randomisation follow-up,
the correlation declines by 0.003 point. Frison and
Pocock [1] also report a slight decline in correlation
amongst more distant pairs of time points post-
randomisation, with the estimated slope being − 0.009
per month apart. So our results are also consistent
with a slight decline.
It is important to make maximum use of the informa-
tion available from other related studies or extrapolation
from other unrelated studies. The more precise the in-
formation, the better we can design the trial. We would
recommend that researchers planning a study with
PROMs as the primary outcome pay careful attention to
any evidence on the validity and frequency distribution
of the PROM and its dimensions.
Strictly speaking, our results and conclusions only
apply to the study population and the outcome mea-
sures used in the 20 RCTs. Further empirical work is
required to see whether these results hold true for
other outcomes, populations and interventions. How-
ever, the PROMs in this paper share many features in
common with other PROM outcomes, i.e. multidi-
mensional, ordinal or discrete response categories
with upper and lower bounds, and skewed distribu-
tions; therefore, we see no theoretical reasons why
these results and conclusions may not be appropriate
for other PROMs.
Table 3 Baseline to post-randomisation follow-up correlations by trial
Trial name Pearson baseline to post-randomisation follow-up correlation
Mean Median No. of correlations SD Minimum Maximum
Leg Ulcer 0.48 0.5 N = 18 0.13 0.23 0.71
NAMEIT 0.46 0.46 N = 54 0.1 0.21 0.63
Homeopathy for CFS 0.5 0.53 N = 5 0.19 0.18 0.65
Acupuncture 0.44 0.45 N = 24 0.12 0.2 0.62
Knee Replacement 0.45 0.48 N = 14 0.16 0.09 0.65
FED 0.5 0.56 N = 18 0.12 0.32 0.7
AIM-High 0.46 0.49 N = 60 0.14 0.16 0.74
PoNDER 0.44 0.47 N = 26 0.11 0.19 0.58
COPD 0.53 0.54 N = 48 0.08 0.37 0.68
Corn Plaster 0.45 0.45 N = 12 0.06 0.33 0.53
PLINY 0.67 0.74 N = 15 0.15 0.41 0.87
3Mg 0.39 0.39 N = 1 - 0.39 0.39
SELF 0.44 0.44 N = 9 0.07 0.31 0.54
BEADS 0.46 0.53 N = 3 0.3 0.14 0.71
DiPALS 0.54 0.57 N = 65 0.18 0.01 0.91
Lifestyle Matters 0.66 0.64 N = 28 0.11 0.45 0.88
IPSU 0.57 0.63 N = 15 0.13 0.34 0.73
POLAR 0.32 0.36 N = 15 0.14 0.04 0.53
PRACTICE 0.36 0.38 N = 6 0.36 −0.13 0.79
STEPWISE 0.53 0.56 N = 28 0.13 0.24 0.72
Totala 0.5 0.51 N = 464 0.15 −0.13 0.91
aThe summary statistics for the total row are calculated from 464 correlations
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Fig. 3 Box and whisker plot of (n = 464) correlations by trial
Table 4 Baseline to post-randomisation follow-up correlations by post-randomisation follow-up time point
Post-
randomisation
follow-up time
point (months)
Pearson baseline to post-randomisation follow-up correlation
Mean Median SD Minimum Maximum No. of correlations
0.25 0.48 0.48 0.44 0.17 0.79 2
1 0.37 0.39 0.28 0.09 0.64 3
1.5 0.49 0.45 0.12 0.33 0.70 14
2 0.55 0.56 0.12 0.26 0.82 34
3 0.48 0.50 0.15 −0.13 0.72 71
4 0.48 0.49 0.09 0.35 0.63 9
4.5 0.48 0.52 0.09 0.32 0.58 9
6 0.54 0.55 0.16 0.04 0.88 121
8 0.43 0.44 0.13 0.21 0.58 9
9 0.62 0.62 0.16 0.38 0.91 16
10 0.45 0.43 0.08 0.34 0.58 9
10.5 0.42 0.47 0.12 0.19 0.54 9
12 0.46 0.48 0.14 0.01 0.72 86
16.5 0.41 0.42 0.12 0.23 0.57 8
18 0.47 0.49 0.13 0.16 0.67 27
24 0.51 0.53 0.15 0.17 0.84 37
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Throughout this paper, we only considered the situ-
ation where a single dimension of the PROM is used at
a single endpoint. Sometimes there is more than one
endpoint of interest; PROMs are typically multidimen-
sional (e.g. the SF-36 has eight dimensions). If one of
these dimensions is regarded as more important than
the others, it can be named as the primary endpoint and
the sample size estimates calculated accordingly. The re-
mainder should be consigned to exploratory analyses or
descriptions only.
We have also assumed a rather simple form of the al-
ternative hypothesis that the new treatment/interven-
tion would improve patient-reported outcomes
compared to the control/standard therapy. This form of
Fig. 4 Scatter plot of correlations against post-randomisation follow-up time point with regression line (464 correlations from 20 trials)
Fig. 5 Scatter plot of correlations against post-randomisation follow-up time point with regression line, SF-36 outcomes (282 correlations from
12 trials)
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hypothesis (superiority versus equivalence) may be
more complicated than actually presented. However,
the assumption of a simple form of the alternative hy-
pothesis—that the new treatment/intervention would
improve outcomes compared to the control/standard
therapy—is not unrealistic for most superiority trials
and is frequently used for other clinical outcomes. Wal-
ters gives a more comprehensive discussion of multiple
endpoints and suggests several methods for analysing
PROMs [4].
Overall, 5 of the 464 observed correlations were small
(less than 0.10). Two of these small correlations came
from the PRACTICE trial [26]. In this trial (PRACTICE)
we observed a negative correlation of − 0.13 (n = 36 par-
ticipants) between the baseline and 3 months follow-up
post-randomisation time point for the EQ-5D visual
analogue scale (VAS) and 0.09 (n = 42 participants) be-
tween the baseline and 1 month follow-up. The correla-
tions were based on small sample sizes (n = 36 and 42),
and examination of the scatter plots suggested no outly-
ing values and a random scatter. The EQ-5D VAS out-
come asks respondents to rate their health today on a 0
(the worst health you can imagine) to 100 (best health
you can imagine) visual analogue scale. It may be that
there genuinely is no correlation in the population (of
chronic obstructive pulmonary disease [COPD] patients)
with this outcome.
We calculated several summary correlations to allow
for clustering of the outcomes by trial and the variance
or standard error of the correlation estimate. The overall
summary correlation for the 464 correlations was robust
to the summary measure (mean, median, weighted
mean, clustered mean) and was around 0.50.
Clifton and Clifton [51] comment that baseline imbal-
ance may occur in RCTs and that ANCOVA should be
used to adjust for baseline in the analysis. Clifton et al.
[52] also point out the following theoretical assumptions
for using the ANCOVA method for sample size estima-
tion: (1) the pairs of baseline and post-randomisation
outcomes follow a bivariate normal distribution; (2) the
values of the baseline to post-randomisation follow-up,
r, are the same in both groups; (3) the variances or SDs
of the outcomes are the same in both groups. However,
ANCOVA is known to be robust to departures from the
assumptions of Normality. The work of Heeren and
D’Agostino [53]and Sullivan and D’Agostino [54] sup-
ports the robustness of the two independent samples t
test and ANCOVA when applied to three-, four- and
five-point ordinal scaled data using assigned scores (like
PROMs), in sample sizes as small as 20 subjects per
group.
Conclusions
There is a general consistency in the correlations be-
tween the baseline and follow-up PROMs, with the ma-
jority being in the range from 0.4 to 0.6. The
implications are that we can reduce the sample size in
an RCT by 25% if we use an ANCOVA model, with a
correlation of 0.50, for the design and analysis. When
allowing for the correlation between baseline and follow-
Fig. 6 Scatter plot of correlations against post-randomisation follow-up time point with regression line, EQ-5D Utility outcome (29 correlations
from 12 trials)
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Table 5 Baseline to post-randomisation follow-up correlations by outcome
Outcome Pearson baseline to post-randomisation follow-up correlation
Mean Median SD Minimum Maximum No. of correlations
B-IPQ 0.6 0.6 0 0.6 0.61 2
BACK PAIN 0.24 0.19 0.11 0.17 0.37 3
Barthel Score 0.53 0.53 0.1 0.45 0.6 2
BPRS 0.57 0.57 0.12 0.49 0.65 2
CORE Functioning Dimension 0.56 0.57 0.02 0.54 0.58 3
CORE Risk Dimension 0.26 0.27 0.07 0.19 0.32 3
CORE Symptoms Dimension 0.5 0.49 0.03 0.47 0.54 3
CORE Total Score 0.55 0.53 0.03 0.53 0.58 3
CORE Well Being Dimension 0.5 0.49 0.03 0.47 0.53 3
EORTC Appetite Loss 0.29 0.3 0.09 0.21 0.37 4
EORTC Cognitive Functioning 0.49 0.49 0.08 0.4 0.59 4
EORTC Constipation 0.39 0.4 0.08 0.3 0.48 4
EORTC Diarrhoea 0.25 0.27 0.07 0.16 0.32 4
EORTC Dyspnoea 0.43 0.44 0.06 0.35 0.49 4
EORTC Emotional Functioning 0.51 0.5 0.06 0.46 0.6 4
EORTC Fatigue 0.56 0.56 0.06 0.49 0.63 4
EORTC Financial Difficulties 0.63 0.62 0.07 0.56 0.74 4
EORTC Insomnia 0.44 0.49 0.12 0.26 0.52 4
EORTC Nausea 0.21 0.18 0.06 0.16 0.3 4
EORTC Pain 0.48 0.48 0.08 0.39 0.58 4
EORTC Physical Functioning 0.59 0.58 0.07 0.52 0.68 4
EORTC QoL 0.55 0.57 0.08 0.44 0.61 4
EORTC Role Functioning 0.54 0.54 0.04 0.5 0.59 4
EORTC Social Functioning 0.51 0.5 0.06 0.43 0.59 4
EPDS 0.49 0.49 0.04 0.47 0.52 2
EQ-5D Utility Score 0.55 0.54 0.13 0.32 0.87 29
EQ-5D VAS 0.41 0.46 0.2 −0.13 0.67 21
GSES 0.52 0.56 0.08 0.44 0.58 3
LEG PAIN 0.16 0.11 0.16 0.04 0.34 3
MFI General Fatigue 0.18 0.18 NA 0.18 0.18 1
MFI Mental Fatigue 0.53 0.53 NA 0.53 0.53 1
MFI Physical Fatigue 0.5 0.5 NA 0.5 0.5 1
MFI Reduced Activity 0.65 0.65 NA 0.65 0.65 1
MFI Reduced Motivation 0.61 0.61 NA 0.61 0.61 1
ODI 0.36 0.36 0.05 0.31 0.41 3
ONS Well-Being 0.62 0.62 NA 0.62 0.62 1
PHQ9 0.66 0.66 0.08 0.53 0.76 6
PISQ-31 Behaviour/Emotion 0.73 0.73 NA 0.73 0.73 1
PISQ-31 Partner Related Factor 0.63 0.63 NA 0.63 0.63 1
PISQ-31 Physical Factor 0.35 0.35 NA 0.35 0.35 1
PISQ-31 Total Score 0.62 0.62 NA 0.62 0.62 1
SF-36 General Health 0.6 0.58 0.08 0.49 0.79 29
SF-36 Mental Component Summary 0.54 0.55 0.12 0.33 0.79 17
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up outcome in the sample size calculation, it is prefera-
ble to be conservative and use existing data that are rele-
vant to your outcome and your population if they are
available. Secondly, be wary of having an ’automatic’ rule
of adjusting your required sample size downwards by
25% just because you have a baseline assessment.
There is a slight decline in correlation between base-
line and more distant post-randomisation follow-up time
points. Finally, we would stress the importance of a sam-
ple size calculation (with all its attendant assumptions)
and also stress that any such estimate is better than no
sample size calculation at all, particularly in a trial proto-
col [55, 56]. The mere fact of calculation of a sample size
means that a number of fundamental issues have been
considered: what is the main outcome variable, what is a
clinically important effect, and how is it measured? The
investigator is also likely to have specified the method
and frequency of data analysis. Thus, protocols that are
explicit about sample size are easier to evaluate in terms
of scientific quality and the likelihood of achieving
objectives.
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Table 5 Baseline to post-randomisation follow-up correlations by outcome (Continued)
Outcome Pearson baseline to post-randomisation follow-up correlation
Mean Median SD Minimum Maximum No. of correlations
SF-36 Mental Health 0.57 0.57 0.11 0.37 0.83 27
SF-36 Pain 0.49 0.51 0.13 0.2 0.71 29
SF-36 Physical Component Summary 0.56 0.6 0.21 0.14 0.84 17
SF-36 Physical Functioning 0.64 0.63 0.17 0.01 0.91 29
SF-36 Role-Emotional 0.42 0.43 0.11 0.12 0.68 31
SF-36 Role-Physical 0.39 0.35 0.12 0.21 0.67 29
SF-36 Social Functioning 0.44 0.45 0.1 0.24 0.63 29
SF-36 Vitality 0.55 0.53 0.1 0.43 0.82 29
SF-36 Health Change 0.32 0.32 0.11 0.24 0.4 2
SF-6D 0.5 0.48 0.09 0.37 0.64 14
Sleep Apnoea QoL 0.56 0.6 0.12 0.35 0.65 5
SPADI 0.47 0.47 0.03 0.44 0.5 3
SPADI Disability 0.49 0.51 0.06 0.43 0.54 3
SPADI Pain 0.36 0.38 0.05 0.31 0.4 3
VAS Pain 0.41 0.41 0.07 0.33 0.48 4
WOMAC Pain 0.26 0.26 NA 0.26 0.26 1
WOMAC Physical Function 0.46 0.46 NA 0.46 0.46 1
WOMAC Stiffness 0.09 0.09 NA 0.09 0.09 1
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